AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma

Gastroenterology. 2022 Mar;162(3):937-951. doi: 10.1053/j.gastro.2021.12.275.

Authors

Osama Altayar¹, Raj Shah², Charissa Y Chang³, Yngve Falck-Ytter⁴, Andrew J Muir⁵

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
² Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Division of Liver Diseases, Recanati Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ Division of Gastroenterology and Hepatology, Veterans Affairs Northeast Ohio Health Care System, Cleveland, Ohio; Case Western Reserve University School of Medicine, Cleveland, Ohio.
⁵ Division of Gastroenterology, Department of Medicine, School of Medicine, Duke University, Durham, North Carolina.

PMID: 35210015
DOI: 10.1053/j.gastro.2021.12.275

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Anilides / therapeutic use
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / administration & dosage
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / physiopathology
Carcinoma, Hepatocellular / secondary
Carcinoma, Hepatocellular / surgery
Chemoembolization, Therapeutic
Chemotherapy, Adjuvant
Hepatectomy
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Liver Neoplasms / physiopathology
Liver Neoplasms / surgery
Liver Transplantation
Phenylurea Compounds / therapeutic use
Pyridines / therapeutic use
Quinolines / therapeutic use
Ramucirumab
Retreatment
Sorafenib / therapeutic use

Substances

Anilides
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Phenylurea Compounds
Pyridines
Quinolines
cabozantinib
regorafenib
Bevacizumab
atezolizumab
Sorafenib
pembrolizumab
lenvatinib